Plachouri Kerasia-Maria, Florou Vaia, Georgiou Vasileios, Georgiou Sophia
Dermatology Department, University General Hospital of Patras, University of Patras, 265 04 Rio, Greece.
Division of Oncology, Department of Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 841112, USA.
Cancers (Basel). 2023 Jun 9;15(12):3126. doi: 10.3390/cancers15123126.
The advent of immunotherapy and targeted therapies in treating dermatological malignancies has dramatically changed the landscape of dermato-oncology in recent years. Their superior efficacy compared to previous therapeutic options, such as chemotherapy, has resulted in their use in treating devastating malignancies, such as melanoma or unresectable/metastatic basal cell and squamous cell carcinoma. Skin toxicity is a critical safety consideration, among other adverse reactions, that can occur under treatment with these agents. This article aims to summarize the cutaneous side effects of immune checkpoint inhibitors and targeted dermato-oncological therapies. Although the skin side effects of these agents are primarily mild, they can occasionally affect the decision for treatment continuation and the quality of life of the affected patients. Therefore, physicians must be acquainted with the specific cutaneous toxicity profile of such treatments to mitigate their impact on the patients and optimize the overall outcome of dermato-oncological therapy.
近年来，免疫疗法和靶向疗法在治疗皮肤恶性肿瘤方面的出现极大地改变了皮肤肿瘤学的格局。与化疗等先前的治疗选择相比，它们具有卓越的疗效，这使得它们被用于治疗诸如黑色素瘤或不可切除/转移性基底细胞癌和鳞状细胞癌等严重恶性肿瘤。皮肤毒性是这些药物治疗过程中可能出现的关键安全考量因素，除此之外还有其他不良反应。本文旨在总结免疫检查点抑制剂和靶向皮肤肿瘤学疗法的皮肤副作用。尽管这些药物的皮肤副作用主要为轻度，但它们偶尔会影响继续治疗的决策以及受影响患者的生活质量。因此，医生必须熟悉此类治疗的特定皮肤毒性特征，以减轻其对患者的影响，并优化皮肤肿瘤学治疗的总体结果。
